Regeneron Pharmaceuticals Inc (LTS:0R2M)
$ 827.21 -6.645 (-0.8%) Market Cap: 91.15 Bil Enterprise Value: 84.05 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 93/100

Regeneron Pharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript

Feb 14, 2023 / 02:20PM GMT
Release Date Price: $752.91 (-1.19%)
David Reed Risinger
Leerink Partners LLC, Research Division - Senior MD

So good morning, everybody, and thank you for joining our session with Regeneron. My name is Dave Risinger. I'm responsible for diversified biopharmaceuticals coverage at SVB Securities. And on behalf of the firm, it's very much my pleasure to welcome senior executives from Regeneron.

So with us today, we have Izzy Lowy, who is Senior Vice President of Clinical Development for Oncology; Andres Sirulnik, Senior Vice President of Clinical Development for Hematology; and Ryan Crowe, Vice President of Investor Relations.

And so with that, let me turn it over to Ryan to read some disclaimers and then we'll take it from there.

Ryan Crowe
Regeneron Pharmaceuticals, Inc. - VP of IR

Thanks, Dave. It's great to be here, and I appreciate the invitation to present at the SVB Securities Global Biopharma Conference.

Before we start, I'd like to remind you that remarks made today may include forward-looking statements about Regeneron. Each forward-looking statement is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot